COMPARATIVE ADHERENCE TRAJECTORIES OF ORAL FINGOLIMOD AND INJECTABLE DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS

被引：0
|
作者：
Earla, J. R. [1 ]
Hutton, G. J. [2 ]
Thornton, J. D. [1 ]
Chen, H. [1 ]
Johnson, M. L. [1 ]
Aparasu, R. [1 ]
机构：
[1] Univ Houston, Houston, TX USA
[2] Baylor Coll Med, Med Ctr, McNair Campus, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND104
引用
收藏
页码：S279 / S279
页数：1
相关论文
共 50 条
  • [1] Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
    Earla, Jagadeswara R.
    Hutton, George J.
    Thornton, J. Douglas
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 2187 - 2199
  • [2] Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis
    Earla, Jagadeswara Rao
    Hutton, George Joseph
    Thornton, J. Douglas
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 118 - 118
  • [3] Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOTHERAPY, 2023, 43 (06): : 473 - 484
  • [4] COMPARATIVE ADHERENCE TRAJECTORIES ACROSS ORAL DISEASE-MODIFYING AGENTS IN MULTIPLE SCLEROSIS
    Earla, J. R.
    Hutton, G. J.
    Aparasu, R. R.
    VALUE IN HEALTH, 2022, 25 (07) : S303 - S303
  • [5] Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara R.
    Hutton, George J.
    Thornton, Douglas J.
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOTHERAPY, 2021, 41 (05): : 440 - 450
  • [6] Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Bentley, John P.
    Aparasu, Rajender R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 85
  • [7] Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis (vol 43, pg 473, 2023)
    Earla, J. R.
    Li, J.
    Hutton, G. J.
    Johnson, M. L.
    Aparasu, R. R.
    PHARMACOTHERAPY, 2024, 44 (09): : 753 - 753
  • [8] Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
    Earla, Jagadeswara Rao
    Hutton, George J.
    Thornton, J. Douglas
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2021, 2
  • [9] Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis
    E. Ann Yeh
    B. Weinstock-Guttman
    Advances in Therapy, 2011, 28 : 270 - 278
  • [10] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
12345